Enlivex Initiates Promising Trial for Psoriatic Arthritis
Company Announcements

Enlivex Initiates Promising Trial for Psoriatic Arthritis

Enlivex (ENLV) has released an update.

Enlivex Therapeutics has announced the successful dosing of the first patient in a Phase I trial to test Allocetra, a potential new treatment for psoriatic arthritis. The study aims to recruit six patients unresponsive to conventional therapies, exploring Allocetra’s safety and therapeutic effects. This development could position Enlivex at the forefront of addressing significant unmet needs in a growing psoriatic arthritis market.

For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyEnlivex completes dosing, follow-up for first patient in study of Allocetra
TipRanks Auto-Generated NewsdeskEnlivex Advances Allocetra Trial for Knee Osteoarthritis
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App